No Shocker Here: Theravance Gets FDA "Complete Response" For Telavancin
This article was originally published in The Pink Sheet Daily
Executive Summary
Telavancin NDA for nosocomial pneumonia on hold as FDA asks for more mortality data while it assesses new requirements for HAP antibiotics.
You may also be interested in...
Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia
Theravance has received two complete response letters but says it does not plan to do additional clinical studies for the new indication; Vibativ production has been halted in the U.S. and its marketing authorization withdrawn in Europe.
Amid A Flurry Of EU Positive Opinions Benlysta And Yervoy Shine, While Fampyra Is Reborn
The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.
Amid A Flurry Of EU Positive Opinions Benlysta And Yervoy Shine, While Fampyra Is Reborn
The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: